Clinical Trial Update: Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the impact of Orteronel on QT/QTc interval in patients with metastatic castration-resistant prostate cancer; results were posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Orteronel (Orteronel)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-06-01